Without giving details, in March, Aspen said under the first phase of the review it would split its South African commercial pharmaceuticals business into two divisions to sharpen its focus. On Wednesday it advised shareholders in a brief statement to exercise caution when dealing in the companyâ€™s shares. --Reuters--